A detailed history of Kynam Capital Management, LP transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Kynam Capital Management, LP holds 1,576,549 shares of VERA stock, worth $74.1 Million. This represents 5.72% of its overall portfolio holdings.

Number of Shares
1,576,549
Previous 1,543,669 2.13%
Holding current value
$74.1 Million
Previous $55.8 Million 24.74%
% of portfolio
5.72%
Previous 4.35%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$34.09 - $46.71 $1.12 Million - $1.54 Million
32,880 Added 2.13%
1,576,549 $69.7 Million
Q2 2024

Aug 14, 2024

BUY
$33.72 - $48.82 $569,261 - $824,179
16,882 Added 1.11%
1,543,669 $55.8 Million
Q1 2024

May 15, 2024

SELL
$14.91 - $49.14 $31.7 Million - $104 Million
-2,123,552 Reduced 58.17%
1,526,787 $65.8 Million
Q4 2023

Feb 14, 2024

BUY
$9.29 - $16.0 $6.45 Million - $11.1 Million
694,286 Added 23.49%
3,650,339 $56.1 Million
Q3 2023

Nov 14, 2023

SELL
$13.71 - $19.64 $602,513 - $863,119
-43,947 Reduced 1.46%
2,956,053 $40.5 Million
Q2 2023

Aug 14, 2023

SELL
$6.11 - $17.83 $2.28 Million - $6.64 Million
-372,428 Reduced 11.04%
3,000,000 $48.2 Million
Q1 2023

May 15, 2023

BUY
$5.41 - $18.3 $10.6 Million - $35.9 Million
1,963,330 Added 139.33%
3,372,428 $26.2 Million
Q4 2022

Feb 14, 2023

SELL
$15.74 - $22.19 $2 Million - $2.82 Million
-127,083 Reduced 8.27%
1,409,098 $27.3 Million
Q3 2022

Nov 14, 2022

BUY
$13.27 - $22.31 $178,733 - $300,493
13,469 Added 0.88%
1,536,181 $32.7 Million
Q2 2022

Aug 15, 2022

BUY
$12.82 - $23.4 $13.1 Million - $23.9 Million
1,020,384 Added 203.13%
1,522,712 $20.7 Million
Q1 2022

May 13, 2022

BUY
$17.8 - $28.06 $4.43 Million - $6.98 Million
248,879 Added 98.2%
502,328 $11.8 Million
Q4 2021

Feb 14, 2022

BUY
$15.01 - $35.8 $3.8 Million - $9.07 Million
253,449 New
253,449 $6.77 Million

Others Institutions Holding VERA

About Vera Therapeutics, Inc.


  • Ticker VERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,042,300
  • Market Cap $1.27B
  • Description
  • Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...
More about VERA
Track This Portfolio

Track Kynam Capital Management, LP Portfolio

Follow Kynam Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kynam Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Kynam Capital Management, LP with notifications on news.